Novartis

To discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering.

Launch date

1970

Employees

Market cap

Net debt

-

Enterprise valuation

$245.4b (Public information from Jul 2024)

Company register number CHE-106.054.058

Basel Canton of Basel-Stadt (HQ)

http://www.novartis.com

https://twitter.com/novartis https://www.facebook.com/novartis https://www.linkedin.com/company/novartis/

Corporate Venture Fund: dRx Capital, Novartis Venture Fund

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	49.9b	52.9b	51.8b	46.7b	48.8b	50.6b	51.1b
% growth	3 %	6 %	(2 %)	(10 %)	5 %	4 %	1 %
EBITDA	17.2b	33.1b	16.4b	18.5b	19.3b	20.5b	20.9b
% EBITDA margin	34 %	63 %	32 %	40 %	40 %	40 %	41 %
Profit	8.1b	24.0b	7.0b	14.9b	10.2b	11.9b	12.8b
% profit margin	16 %	45 %	13 %	32 %	21 %	24 %	25 %
EV / revenue	4.8x	3.9x	3.9x	4.7x	4.3x	4.1x	4.0x
EV / EBITDA	14.0x	6.2x	12.4x	11.9x	10.9x	10.2x	9.8x
R&D budget	9.0b	9.5b	10.0b	11.4b	-	-	-
R&D % of revenue	18 %	18 %	19 %	24 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Curative Ventures Wellington Partners BioAdvance	N/A	-
Apr 1995	N/A	N/A	IPO
Feb 2018	Bill & Melinda Gates Foundation	$6.5m	Grant
Total Funding		$6.5m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by Novartis Dec 2016

ONL Therapeutics

Encore Vision Inc.

ACQUISITION by Novartis Dec 2016

Caribou Biosciences

exited

ACQUISITION by Novartis Dec 2009

Pear Therapeutics

exited

Intellia Therapeutics

exited

exited

The Medicines Company

ACQUISITION by Novartis Nov 2019

ACQUISITION by Novartis Nov 2018